Antithrombotic drugs are special drugs that help to prevent the formation of thrombus or clot. These drugs are used to reduce the formation of blood clots by reducing the capability of body to form a blood clot. Antithrombotic drugs act by preventing the production of vitamin K in the liver. Anticoagulant, antiplatelet, and thrombolytic agents are different types of antithrombotic agents that act by different clotting processes. Arterial & venous thrombosis, two types of thrombosis, can be treated with the antithrombotic drugs.
According to study, “Antithrombotic Drugs Global Market Opportunities And Strategies To 2030” the key companies operating in the global antithrombotic drugs market are Mylan N.V., Aspen Holdings, Sanofi, Pfizer Inc, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company., Hebei Changshan Biochemical Pharmaceutical Co. Ltd., Eisai Co., Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, OPOCRIN S.P.A, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., SARIA SE & Co. KG, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd, Shenzhen Techdow Pharmaceutical Co., Ltd, Yino Pharma Limited, Teva Pharmaceutical Industries Ltd., and others.
Based on product type, antithrombotic drugs market is segmented as anti-fibrinolytics drugs, anti-coagulant drugs, and anti-platelet drug and others. Based on drug class, market is segmented as heparin, dabigatran, apixaban, rivaroxaban, fondaparinux, and others. Based on route of administration, market is segmented as injectable and oral. Based on application, market is segmented as blood clot & thromboembolic treatment drugs, hyperlipidemia treatment, prophylactic treatment and other applications. Based on distribution channel, market is segmented as online pharmacy, hospital pharmacy, retail pharmacy and others. In addition, based on end-users, market is segmented as homecare, hospitals, specialty centers and others.
The antithrombotic drugs market is driven by rise in demand for novel oral anticoagulants, followed by growth in ageing population, increase in prevalence of thrombosis, growth in developments in the pharmaceutical industry and increase in prevalence of cardiac & hereditary diseases. However, high cost & side effects of antithrombotic drugs and stringent regulatory policies may impact the market.
Based on geography, the North-American region dominates the global antithrombotic drugs market owing to increase in prevalence of cardiovascular & blood-related diseases and growth in development of new drugs in the region. The Asian-Pacific and European regions are estimated to witness higher growth rate due to presence of high population based countries and presence of global marketed players over the forecast period. It is predicted that future of the global market will be bright as a result of increase in research & development (R&D) activities for new drug development and up-gradation in antithrombotic drug as well as the innovative product launches during the forecast period. The global antithrombotic drugs market reached approximately US $35,801.9 million in 2019 and is anticipated to grow at a CAGR of 7.7% to nearly US $44,702.6 million by 2022. The market is probable to growth to US $55,172.2 million in 2025 at a CAGR of 7.3% and to US $72,996.5 million in 2030 at a CAGR of 5.8%.
For More Information, Click on the Link Below:-
Ankur Gupta, Head Marketing & Communications